Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a rare genetic condition that is also known by several other names. One of the synonyms for HLRCC is Reed's Syndrome, named after Dr. Alan Reed who first described the condition in 1973. Another synonym is Familial Leiomyomatosis Renal Cell Carcinoma (HLRCC), which highlights the familial nature of the disease and its association with renal cell carcinoma.
HLRCC is an inherited condition that primarily affects the skin and kidneys. It is caused by mutations in the FH gene, which is responsible for producing an enzyme called fumarate hydratase. This enzyme plays a crucial role in the energy production process within cells. Mutations in the FH gene lead to a deficiency of fumarate hydratase, resulting in the development of leiomyomas (benign smooth muscle tumors) in various parts of the body, particularly in the skin and uterus.
One of the distinguishing features of HLRCC is the increased risk of developing renal cell carcinoma (RCC), a type of kidney cancer. RCC typically occurs at a younger age in individuals with HLRCC compared to the general population. The risk of developing RCC in HLRCC patients is estimated to be around 15-30%.
It is important to note that HLRCC is a hereditary condition, meaning it can be passed down from generation to generation within families. Genetic testing can be performed to identify mutations in the FH gene, allowing for early detection and management of the condition.
In summary, Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a rare genetic condition that is also known as Reed's Syndrome or Familial Leiomyomatosis Renal Cell Carcinoma. It is characterized by the development of leiomyomas in the skin and uterus, as well as an increased risk of renal cell carcinoma. HLRCC is caused by mutations in the FH gene and is inherited in a familial manner.